Loading organizations...

§ Private Profile · Irvine, CA, USA
A small sticker that monitors blood pressure continuously
Vena Vitals has raised $130K across 1 funding round.
Key people at Vena Vitals.
Vena Vitals was founded in 2019 by Josh Kim (Founder) and Michelle Khine (Founder) and Ray Liu (Founder).
Vena Vitals has raised $130K in total across 1 funding round.
Vena Vitals makes a small sticker that monitors blood pressure continuously. We've shown that it works in the operating room and is as accurate as the best tools doctors have today, at a fraction of the cost. We're a team of health tech scientists with multiple past startups and exits, and we've built products that have scaled to over 2M users.
Vena Vitals was founded in 2019 by Josh Kim (Founder) and Michelle Khine (Founder) and Ray Liu (Founder).
Vena Vitals has raised $130K in total across 1 funding round.
Vena Vitals's investors include Draper Associates, First Star Ventures, Hustle Fund, Innospark Ventures, Locus Ventures.
Vena Vitals develops a small, flexible, and non-invasive sticker sensor that continuously monitors blood pressure with clinical-grade accuracy comparable to invasive arterial lines used in operating rooms. This wearable device captures beat-to-beat blood pressure data in real time, enabling early detection of critical cardiovascular events such as hypotension and hypertension. Unlike traditional cuff-based monitors that provide only periodic snapshots, Vena Vitals’ technology offers continuous monitoring suitable for both acute hospital care and long-term outpatient use. The company’s mission centers on democratizing access to continuous cardiovascular monitoring, improving patient outcomes by making hospital-grade blood pressure data accessible outside intensive care settings[1][2][6].
Founded by experienced health tech entrepreneurs, Vena Vitals serves hospitals, surgical centers, and patients requiring ongoing cardiovascular monitoring, addressing the unmet need for accurate, real-time blood pressure data without invasive procedures or bulky equipment. The company has demonstrated strong growth momentum through clinical validations involving over 500 patients, prestigious awards, and backing from prominent investors and accelerators such as Y Combinator and MedTech Innovator[1][6].
Vena Vitals was founded in 2019 by Ray Liu, Michelle Khine, and Josh Kim, veterans in health technology with multiple successful exits. The idea originated from technology developed during a PhD project at the University of California, Irvine, focusing on non-invasive continuous blood pressure monitoring using soft, stretchable sensors that adhere to the skin over palpable arteries. Early traction included clinical validation in operating rooms and intensive care units, proving the device’s accuracy and utility in critical care settings. The company’s innovation earned top honors like the 2020 MedTech Innovator Execution Award and the AdvaMed Accel Virginia Shimer Rybski Memorial Award, signaling strong recognition within the medtech community[1][5].
Vena Vitals rides the growing trend toward wearable health technology and continuous physiological monitoring, addressing a critical gap in cardiovascular care. The timing is favorable due to increasing awareness of hypertension’s global burden and the limitations of current intermittent blood pressure monitoring methods. Market forces such as rising chronic disease prevalence, demand for remote patient monitoring, and advances in flexible electronics support Vena Vitals’ growth. By enabling continuous, non-invasive blood pressure tracking, Vena Vitals influences the broader ecosystem by pushing forward the standard of care in cardiovascular health, facilitating earlier interventions, and reducing healthcare costs associated with undetected blood pressure fluctuations[1][2][4].
Looking ahead, Vena Vitals is poised to expand its market presence by pursuing FDA approval and scaling use cases beyond hospitals into home health monitoring, particularly for sleep apnea and chronic cardiovascular conditions. Trends such as telemedicine, personalized health data, and AI-driven analytics will likely shape their journey, enhancing the device’s predictive capabilities and integration with digital health platforms. As continuous blood pressure monitoring becomes a new standard, Vena Vitals’ influence may grow from a niche clinical tool to a mainstream health technology, transforming how blood pressure is managed globally and improving outcomes for millions at risk of cardiovascular disease[6][1].
This evolution ties back to their core mission: making continuous cardiovascular monitoring accessible and actionable through a simple sticker, fundamentally changing blood pressure management one patient at a time.
Vena Vitals has raised $130K across 1 funding round. Most recently, it raised $130K Seed in August 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2020 | $130K Seed | — | Draper Associates, First Star Ventures, Hustle Fund, Innospark Ventures, Locus Ventures | Announced |
Key people at Vena Vitals.